A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-ß trap (M7824) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
To be updated